Sign In
Buy VOR
$19.14
-0.610 (-3.09%)
At Close: Jul 10, 2026
Vor Bio Appoints David Zaccardelli to Board of Directors
04:01pm, Tuesday, 07'th Jul 2026
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zacc
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
02:39pm, Tuesday, 07'th Jul 2026
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitacicept, a dual BAFF/APRIL inhibitor with multiple China approvals. VOR holds $491.5 million in cash,
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Thursday, 02'nd Jul 2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Co
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
08:31am, Monday, 08'th Jun 2026
First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating stati
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
08:30am, Monday, 08'th Jun 2026
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Monday, 01'st Jun 2026
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026,
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
08:30am, Thursday, 28'th May 2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corpora
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:30am, Wednesday, 13'th May 2026
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
10:55am, Thursday, 07'th May 2026
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 04'th May 2026
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Comp
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
10:56am, Monday, 20'th Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the po
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Update
02:20am, Wednesday, 15'th Apr 2026
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 5,687,983 shares, a growth of 66.5%
Ra Capital Management, L.P. Sells 484,104 Shares of Vor Biopharma (NASDAQ:VOR) Stock
04:19am, Sunday, 12'th Apr 2026
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock in a transaction on Wednesday, April 8th. The shares were sold at an
Ra Capital Management, L.P. Sells 135,201 Shares of Vor Biopharma (NASDAQ:VOR) Stock
04:19am, Sunday, 12'th Apr 2026
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 135,201 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average pri
